Whitehawk Therapeutics Inc
$4.22+3.69%(+$0.15)
TickerSpark Score
62/100
50
Valuation
20
Profitability
55
Growth
84
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WHWK research report →
52-Week Range68% of range
Low $1.57
Current $4.22
High $5.50
Companyir.whitehawktx.com
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
- CEO
- David J. Lennon
- IPO
- 2017
- Employees
- 40
- HQ
- Pacific Palisades, CA, US
Price Chart
+112.06% · this period
Valuation
- Market Cap
- $208.69M
- P/E
- -2.52
- P/S
- 0.00
- P/B
- 2.51
- EV/EBITDA
- -1.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -79.63%
- ROIC
- -105.62%
Growth & Income
- Revenue
- $7.14M · -72.50%
- Net Income
- $-20,596,000 · 67.66%
- EPS
- $-0.33 · 86.02%
- Op Income
- $-114,400,000
- FCF YoY
- -60.10%
Performance & Tape
- 52W High
- $5.50
- 52W Low
- $1.57
- 50D MA
- $3.91
- 200D MA
- $2.74
- Beta
- 0.71
- Avg Volume
- 284.34K
Get TickerSpark's AI analysis on WHWK
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Dugan Margaret | other | 19,132 |
| May 14, 26 | BALL BRYAN | other | 51,020 |
| May 14, 26 | Giacobello Scott M. | other | 38,265 |
| May 14, 26 | Lennon David James | other | 51,021 |
| May 14, 26 | Castelein Caley | other | 2,072,756 |
| May 14, 26 | Castelein Caley | other | 255,102 |
| May 12, 26 | Avoro Capital Advisors LLC | other | 6,377,714 |
| Apr 15, 26 | Giacobello Scott M. | sell | 77,000 |
| Apr 16, 26 | Giacobello Scott M. | sell | 141,600 |
| Apr 13, 26 | BALL BRYAN | sell | 26,389 |
Our WHWK Coverage
We haven't published any research on WHWK yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate WHWK Report →